The BPHL Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat human T-lymphocyte line. This product features targeted disruption of the BPHL gene, encoding a serine hydrolase responsible for prodrug activation, creating a reliable loss-of-function model for investigating antiviral prodrug metabolism in a leukemic T-cell context. The use of a polyclonal knockout population enables robust, scalable studies without the clonal artifacts associated with single-cell-derived lines.
Jurkat cells are a well-established suspension cell line originating from a patient with acute lymphoblastic leukemia. As a model of T lymphocyte biology, they support research on adaptive immune responses, T-cell receptor signaling, and apoptosis regulation. Their genetic tractability and rapid growth make them an ideal host for gene-edited models, facilitating high-throughput assays in immunology and cancer biology.
BPHL encodes a serine hydrolase that catalyzes the hydrolytic conversion of the antiviral prodrug valacyclovir to its active metabolite acyclovir. Acyclovir subsequently acts as a competitive inhibitor of viral DNA polymerase, interfering with viral replication. In this pathway, valacyclovir serves as the primary substrate, while thymidine kinase participates in further phosphorylation of acyclovir to its triphosphate form. The downstream effectors include acyclovir and ganciclovir, which target viral DNA polymerases. BPHL thus functions upstream of acyclovir generation, and its disruption abolishes the activation of valacyclovir, rendering cells insensitive to antiviral strategies. upstream regulators of BPHL remain largely undefined, though cellular stress and drug exposure may influence expression.
In Jurkat cells, BPHL knockout provides a unique platform for dissecting prodrug metabolism specifically within T-cell leukemia models. The loss of BPHL activity mimics scenarios of impaired drug activation, such as in antiviral drug resistance or metabolic disorders, allowing researchers to study how leukemic T cells process xenobiotic compounds. This model is particularly valuable for understanding the intersection of T-cell signaling and drug metabolism, as Jurkat cells retain key features of T lymphocytes, including their signaling networks and apoptotic pathways.
Researchers can employ these knockout cells in a variety of assays, including HPLC-based valacyclovir activation assays, LC-MS quantification of acyclovir, cell viability assessments under prodrug treatment, and molecular analyses by western blotting and RT-qPCR for BPHL expression. Drug sensitivity assays further enable the evaluation of antiviral agents like valacyclovir and ganciclovir. These applications support pharmacokinetic modeling, drug resistance mechanism studies, and the preclinical assessment of antiviral prodrugs. For further inquiries regarding this product, please contact Ascent Research.
